2023 ESTRO-EANO 胶质母细胞瘤靶区划定和放疗细节指南

2023-04-12 欧洲放射肿瘤学学会 Radiotherapy and Oncology 发表于安徽省

该指南旨在更新现有的关于成人胶质母细胞瘤患者临床靶区 (CTV) 划定的欧洲联合共识。

中文标题:

2023 ESTRO-EANO 胶质母细胞瘤靶区划定和放疗细节指南

英文标题:

ESTRO-EANO guideline on target delineation and radiotherapy details for glioblastoma

发布机构:

欧洲放射肿瘤学学会

发布日期:

2023-04-12

简要介绍:

目前的 ESTRO-EANO 指南报告了胶质母细胞瘤靶标描绘的新标准,并完善了 ESTRO-ACROP/EORTC 标准。

GTV 在 MRI 上被定义为 T1 对比增强肿瘤(对于仅活检患者)和/或切除腔加上残留的对比增强肿瘤(如果存在)。

应在 GTV 周围留出 15 毫米的边缘以生成 CTV,编辑时考虑到肿瘤扩散的解剖障碍。

不建议将水肿包括在 CTV 中,而 T2/FLAIR 信号异常可能代表非强化肿瘤,应考虑将其包括在 CTV 中。

相关资料下载:
[AttachmentFileName(sort=1, fileName=2023 ESTRO-EANO 胶质母细胞瘤靶区划定和放疗细节指南.pdf)] GetToolGuiderByIdResponse(projectId=1, id=2b9fa1c003111191, title=2023 ESTRO-EANO 胶质母细胞瘤靶区划定和放疗细节指南, enTitle=ESTRO-EANO guideline on target delineation and radiotherapy details for glioblastoma, guiderFrom=Radiotherapy and Oncology, authorId=0, author=, summary=该指南旨在更新现有的关于成人胶质母细胞瘤患者临床靶区 (CTV) 划定的欧洲联合共识。, cover=https://img.medsci.cn/Random/doctor-is-working-at-the-hospital-PTE4SCK.jpg, journalId=0, articlesId=null, associationId=1624, associationName=欧洲放射肿瘤学学会, associationIntro=, copyright=0, guiderPublishedTime=Wed Apr 12 00:00:00 CST 2023, originalUrl=, linkOutUrl=, content=<p>目前的 ESTRO-EANO 指南报告了胶质母细胞瘤靶标描绘的新标准,并完善了 ESTRO-ACROP/EORTC 标准。</p> <p>GTV 在 MRI 上被定义为 T1 对比增强肿瘤(对于仅活检患者)和/或切除腔加上残留的对比增强肿瘤(如果存在)。</p> <p>应在 GTV 周围留出 15 毫米的边缘以生成 CTV,编辑时考虑到肿瘤扩散的解剖障碍。</p> <p>不建议将水肿包括在 CTV 中,而 T2/FLAIR 信号异常可能代表非强化肿瘤,应考虑将其包括在 CTV 中。</p>, tagList=[TagDto(tagId=5010, tagName=胶质母细胞瘤)], categoryList=[CategoryDto(categoryId=5, categoryName=肿瘤, tenant=100), CategoryDto(categoryId=17, categoryName=神经科, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=5010, articleKeyword=胶质母细胞瘤, articleKeywordNum=6, guiderKeywordId=5010, guiderKeyword=胶质母细胞瘤, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指南, guiderLanguage=1, guiderRegion=2, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=5818, appHits=97, showAppHits=0, pcHits=261, showPcHits=5721, likes=0, shares=54, comments=4, approvalStatus=1, publishedTime=Thu Apr 27 19:57:00 CST 2023, publishedTimeString=2023-04-12, pcVisible=1, appVisible=1, editorId=0, editor=FUNNYMAN, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=3, createdBy=null, createdName=FUNNYMAN, createdTime=Mon Apr 24 21:58:33 CST 2023, updatedBy=2427819, updatedName=梁丽玲, updatedTime=Sat Jan 06 12:21:24 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=安徽省, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=2023 ESTRO-EANO 胶质母细胞瘤靶区划定和放疗细节指南.pdf)])
2023 ESTRO-EANO 胶质母细胞瘤靶区划定和放疗细节指南.pdf
下载请点击:
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2212083, encodeId=49c32212083f1, content=好东西,学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=97ce9366258, createdName=ms9000001150217840, createdTime=Fri Jun 28 11:52:34 CST 2024, time=2024-06-28, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2129138, encodeId=fe7221291382e, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=75456312513, createdName=1001055_3829, createdTime=Fri Apr 28 23:23:12 CST 2023, time=2023-04-28, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2128945, encodeId=90292128945da, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5bf26472850, createdName=ms2000000147841561, createdTime=Fri Apr 28 09:55:02 CST 2023, time=2023-04-28, status=1, ipAttribution=河北省)]
    2024-06-28 ms9000001150217840 来自上海

    好东西,学习了

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2212083, encodeId=49c32212083f1, content=好东西,学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=97ce9366258, createdName=ms9000001150217840, createdTime=Fri Jun 28 11:52:34 CST 2024, time=2024-06-28, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2129138, encodeId=fe7221291382e, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=75456312513, createdName=1001055_3829, createdTime=Fri Apr 28 23:23:12 CST 2023, time=2023-04-28, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2128945, encodeId=90292128945da, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5bf26472850, createdName=ms2000000147841561, createdTime=Fri Apr 28 09:55:02 CST 2023, time=2023-04-28, status=1, ipAttribution=河北省)]
    2023-04-28 1001055_3829 来自江苏省

    学习了

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2212083, encodeId=49c32212083f1, content=好东西,学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=97ce9366258, createdName=ms9000001150217840, createdTime=Fri Jun 28 11:52:34 CST 2024, time=2024-06-28, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2129138, encodeId=fe7221291382e, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=75456312513, createdName=1001055_3829, createdTime=Fri Apr 28 23:23:12 CST 2023, time=2023-04-28, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2128945, encodeId=90292128945da, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5bf26472850, createdName=ms2000000147841561, createdTime=Fri Apr 28 09:55:02 CST 2023, time=2023-04-28, status=1, ipAttribution=河北省)]
    2023-04-28 ms2000000147841561 来自河北省

    #DIA#学习

    0

拓展阅读

哈工大贺强、吴英杰、毛梦团队《自然·通讯》:中性粒细胞搭载酶驱动纳米机器人,精准穿越血脑屏障打击“癌王”脑胶质瘤!

哈工大贺强团队开发 “特洛伊细胞机器人”(Trojanbot),借中性粒细胞趋化性穿越血脑屏障,释放酶驱动纳米机器人,依肿瘤微环境 H₂O₂梯度深入核心,显著提升脑胶质瘤治疗效果。

Nat Commun:满江红等团队研究揭示了AATF在XRCC4介导的NHEJ修复中的关键作用

研究揭示了GSC通过上调凋亡拮抗转录因子(AATF)激活非同源末端连接(NHEJ)来增强其DNA修复能力,从而促进GB的治疗耐药性。

肿瘤免疫微环境,最新Nature!

通过揭示星形胶质细胞在胶质母细胞瘤免疫微环境中的作用机制,本研究不仅有助于深入理解胶质母细胞瘤的免疫逃逸机制,还可能为开发新的免疫治疗策略提供理论基础。

Nature Genetics:告别“批量”模糊:首个大规模单细胞研究,解码胶质母细胞瘤纵向演变的“个体差异”与“普遍规律”

研究借助单细胞组学剖析 GBM 复发,发现复发时恶性细胞减少,胶质 - 神经细胞增多,个体演变轨迹各异,受 MGMT 基因和治疗变异影响,肿瘤与微环境协同变化。

Small:暨南大学/南方医科大学涂盈锋/刘坤研究发现镁微电机的协同氢化疗调节肿瘤微环境抑制胶质母细胞瘤复发

该研究制备了一种基于镁微电机(Mg-Motor-DOX)的多功能系统,原位产生氢气并主动递送化疗药物阿霉素(DOX)。

论文解读/Sun X/ Cui H教授团队揭示HMGN2通过调控CDC20表达促进胶质母细胞瘤增殖的分子机制

该研究揭示了HMGN2通过调控CDC20表达促进胶质母细胞瘤增殖的分子机制,为胶质瘤的治疗提供了新的靶点。

2023 ESTRO/EANO指南:胶质母细胞瘤的靶区勾画和放疗细节

欧洲放射肿瘤学学会(ESTRO,European Society of Radiotherapy & Oncology) · 2023-04-13

2025 加拿大专家共识建议:胶质母细胞瘤的诊断和管理

国外肿瘤科相关专家小组(统称) · 2025-04-01